Efficacy and safety of sodium–glucose cotransporter 2 inhibitors in type 2 diabetes: a meta-analysis of randomized controlled trials for 1 to 2 years
Top Cited Papers
- 1 November 2015
- journal article
- research article
- Published by Elsevier BV in Journal of Diabetes and its Complications
- Vol. 29 (8), 1295-1303
- https://doi.org/10.1016/j.jdiacomp.2015.07.011
Abstract
No abstract availableKeywords
This publication has 45 references indexed in Scilit:
- Canagliflozin: a novel treatment option for type 2 diabetesDrug Design, Development and Therapy, 2013
- Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trialDiabetologia, 2013
- Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trialBMC Medicine, 2013
- Dapagliflozin Versus Glipizide as Add-on Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control With MetforminDiabetes Care, 2011
- Development and potential role of type-2 sodium-glucose transporter inhibitors for management of type 2 diabetesDiabetes Therapy, 2011
- Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trialThe Lancet, 2010
- From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes MellitusDiabetes, 2009
- Sodium-Glucose Cotransport Inhibition With Dapagliflozin in Type 2 DiabetesDiabetes Care, 2008
- Quantifying heterogeneity in a meta-analysisStatistics in Medicine, 2002